Human papillomavirus vaccine update

Current Infectious Disease Reports

Volumn 9, Issue 2, 2007, Pages 151-158

  Ames, Alisa ^b   Gravitt, Patti ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; PLACEBO; VIRUS DNA; WART VIRUS VACCINE;

CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; HEALTH CARE PLANNING; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; NONHUMAN; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PREVALENCE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL BEHAVIOR; SOCIOECONOMICS; SYSTEMIC DISEASE; UTERINE CERVIX CANCER; VIRUS LIKE AGENT; VIRUS STRAIN;

EID: 33947273719     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0011-6     Document Type: Review

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Denny L, Quinn M, Sankaranarayanan R: Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006, 24(Suppl 3):S71-77.
3. Gravitt P, Shah K: A virus-based vaccine may prevent cervical cancer. Curr Infect Dis Rep 2005, 7:125-131.
4. Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1651.
5. Koutsky LA, Harper DM: Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006, 24(Suppl 3):S114-121.
6. Gardasil Prescribing Information. Available at http://www.merck.com/ product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf. Accessed December 7, 2006.
7. Hildesheim A, Herrero R: Effect of a HPV 16/18 vaccine on resolution of infections in women with pre-existing HPV. Presented at the 23rd International Papillomavirus Conference & Clinical Workshop. Prague, Czech Republic; September 1-7, 2006.
8. Stanley M, Lowy DR, Frazer I: Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006, 24(Suppl 3):S106-113.
9. Harper DM, Franco EL, Wheeler CM, et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
10. Villa LL, Ault KA, Giuliano AR, et al.: Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24:5571-5583.
11. Clifford G, Franceschi S, Diaz M, et al.: Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3):S26-34.
12. Palefsky JM, Gillison ML, Strickler HD: Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006, 24(Suppl 3):S140-146.
13. Taira AV, Neukermans CP, Sanders GD: Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10:1915-1923.
14. Barnabas RV, Laukkanen P, Koskela P, et al.: Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3:e138.
15. Roden RB, Yutzy WH, Fallon R, et al.: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270:254-257.
16. Rose RC, White WI, Li M, et al.: Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998, 72:6151-6154.
17. Roden R, Wu TC: Preventative and therapeutic vaccines for cervical cancer. Expert Rev Vaccines 2003, 2:495-516.
18. Goldie SJ, Grima D, Kohli M, et al.: A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106:896-904.
19. Goldie SJ, Kohli M, Grima D, et al.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
20. Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781-789.
21. Merck and Co. Inc.: European Commission approves GARDASIL®, Merck's cervical cancer vaccine [press release]. Available at http://www.merck.com/newsroom/press_releases/product/2006_0922a.html. Accessed December 7, 2006.
22. ACIP provisional recommendations for the use of quadrivalent HPV vaccine. Available at http://www.cdc.gov/nip/recs/provisional_recs/ hpv.pdf. Accessed December 7, 2006.
23. Gravitt PE, Viscidi RP: Measurement of exposure to human papillomaviruses. In Cervical Cancer: From Etiology to Prevention. Edited by Rohan TE, Shah KV. Dordrecht/Boston/London: Kluwer Academic Publishers; 2004:119-141.
24. Winer RL, Lee SK, Hughes JP, et al.: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157:218-226.
25. Eaton DK, Kann L, Kinchen S, et al.: Youth risk behavior surveillance - United States, 2005. MMWR Surveill Summ 2006, 55:1-108.
26. Zimet GD, Liddon N, Rosenthal SL, et al.: Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine 2006, 24(Suppl 3):S201-209.
27. Advisory Committee on Immunization Practices, Vaccines for Children Program: Vaccine to prevent human papillomavirus infection. Available at http://www.cdc.gov/nip/vfc/acip_resolutions/0606hpv.pdf. Accessed December 7, 2006.
28. PATH: PATH to pave the way for cervical cancer vaccines in the developing world [press release]. Available at http://www.path.org/news/ pr060606-cervical_cancer_vaccine.php. Accessed December 7, 2006.
29. Franco EL, Bosch FX, Cuzick J, et al.: Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 2006, 24(Suppl 3): S242-249.
30. Garnett GP, Kim JJ, French K, Goldie SJ: Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl 3): S178-186.
31. Cuzick J, Mayrand MH, Ronco G, et al.: Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006, 24(Suppl 3):S90-97.
32. Arbyn M, Sasieni P, Meijer CJ, et al.: Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006, 24(Suppl 3):S78-89.
33. Cuzick J, Szarewski A, Cubic H, et al.: Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362:1871-1876.
34. Harper DM, Franco EL, Wheeler C, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.